VTVT News and Press, vTv Therapeutics Inc. From 09/26/23

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer PR Newswire Initiation of Clinical Study at Allegheny Health Network Seeks to Provide Treatment Options t...

2023-09-22 05:22:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some investors believe that the market is always correct and that stock prices always accurately reflect reality. As a result, they will rarely if ever buy stocks that are tumbling and that are...

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA PR Newswire Initiation of Clinical Study at Lenox Hill Hospital Seeks to Provide New Option for Treatmen...

2023-08-11 16:43:34 ET vTv Therapeutics press release ( NASDAQ: VTVT ): Q2 GAAP EPS of -$0.07. The Company’s cash position as of June 30, 2023, was $12.6 million compared to $12.1 million as of December 31, 2022. Shares +1.53% . For further d...

HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial...

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer PR Newswire Cantex's once daily, orally administered, azeliragon inhibits interactions of the receptor ...

2023-08-06 12:00:54 ET Only a tiny fraction of adults in the U.S. are using prescription weight loss drugs, while many more are looking forward to taking them if the meds are proven to be safe and effective, a new survey by the healthcare policy organization Kaiser Family Foundation shows. ...

HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin ( TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), announced today that...

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON PR Newswire WESTON, Fla. , June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc ., a clinical-stage pharmaceutical company focused on developing transformative ther...

2023-06-04 12:00:08 ET Billions of dollars in sales across various MedTech markets will be at stake if there is a broader acceptance of weight loss drugs developed by Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), Morgan Stanley argued in a research note last week. Novo N...